Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's ...
From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million ...
K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech ...
Chai Discovery has announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence.
However, in a conversation with Norstella’s VP of thought leadership Dan Chancellor, he explained that pipeline creation has ...
Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...
Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...
A partnership roundup covers deals from IntraGel Therapeutics/UroGen Pharma and Lupin/Tenpoint Therapeutics, FDA approves ...
Pharmaceutical reshoring is constrained by supplier qualification, process validation, FDA compliance readiness, workforce ...
UroGen Pharma has invested in IntraGel Therapeutics and secured an exclusive option to license Tumocure, and Lupin's ...
FDA approval in adult FOP targets disease-driving Activin A biology, addressing progressive heterotopic ossification that ...
Heidi Overton, a UNM-trained physician with Johns Hopkins general surgery training, was selected for FDA commissioner after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results